No annual revenue total was found in Silexion Therapeutics Corp's SEC filings.
Silexion Therapeutics Corp (SLXN) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was -$10.8 million. As of Jun 30, 2026 it held $2.2 million in cash and investments and $425,000 in total debt.
Revenue
—
Net income (TTM)
$-13.96M
+21.8% vs year-ago TTM
Operating cash flow (TTM)
$-12.43M
-17.9% vs year-ago TTM
Free cash flow (TTM)
$-12.43M
-17.7% vs year-ago TTM
EPS (TTM)
$-8.98
-103.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
3.33M
-100.0% vs prior year
Net cash
$1.80M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- SLXN (Nasdaq), SLXNW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Ramat Gan, Israel
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2022416
- Former names
- Biomotion Sciences (until Aug 15, 2024)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
|---|---|---|
| Operating income | -$11.6M | -$12.6M |
| Net income | -$11.9M | -$16.5M |
| Diluted EPS | $8.96 | $394.94 |
| Operating cash flow | -$10.8M | -$8.4M |
| Free cash flow | -$10.8M | -$8.4M |
| Total assets | $7.2M | $2.9M |
| Total liabilities | $4.6M | $6.9M |
| Stockholders' equity | $2.6M | -$4.0M |
| Cash and investments | $6.0M | $1.2M |
| Total debt | $468,000 | $526,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Oct 26, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 30, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Sep 29, 2026 | Sep 28, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 28, 2026 | Sep 28, 2026 |
| 8-K |
Current report
Listing notice
|
Sep 25, 2026 | Sep 25, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Sep 25, 2026 | Sep 25, 2026 |
All 279 Silexion Therapeutics Corp SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.